Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa

The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was developed using a rational design ap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-10, Vol.15 (10), p.e0240896
Hauptverfasser:	Nichols, Timothy C, Levy, Howard, Merricks, Elizabeth P, Raymer, Robin A, Lee, Martin L
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Animals Antigens Bioavailability Biological Availability Biology and Life Sciences Blood coagulation Care and treatment Clotting Coagulation Coagulation factor IX Coagulation factors Committees Disease Models, Animal Dogs Dosage Drug Design Drug dosages Drug Evaluation, Preclinical Evaluation Factor IX Factor IX - administration & dosage Factor IX - chemistry Factor IX - pharmacokinetics Factor IX deficiency Female Health aspects Hemophilia Hemophilia B - blood Hemophilia B - drug therapy Injections, Subcutaneous Intravenous administration Laboratory animals Laboratory tests Male Medicine Medicine and health sciences Models, Molecular Observations Partial Thromboplastin Time Pathology Pharmacodynamics Pharmacokinetics Pharmacological research Pharmacology Prevention Prophylaxis Safety Thromboplastin Time measurement Whole Blood Coagulation Time
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!